Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing

Ruxolitinib, an oral JAK1 and JAK2 inhibitor, is approved in the US for patients with intermediate or high-risk myelofibrosis (MF), a chronic neoplasm associated with aberrant myeloproliferation, progressive bone marrow fibrosis, splenomegaly, and burdensome symptoms. Phase III clinical studies have...

Descripción completa

Detalles Bibliográficos
Autores principales: Mesa, Ruben A, Cortes, Jorge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4222119/
https://www.ncbi.nlm.nih.gov/pubmed/24283870
http://dx.doi.org/10.1186/1756-8722-6-79

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4222119/
https://www.ncbi.nlm.nih.gov/pubmed/24283870
http://dx.doi.org/10.1186/1756-8722-6-79

Ejemplares similares